Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome
A Phase II, Multicentre, Randomised, Double-blind, Parallel and Controlled With Placebo Pilot Study to Evaluate the Efficacy and Safety of a Single Dose of Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment, in Patients With Primary Myofascial Syndrome of Cervical and Dorsal Localisation
Sponsor: Ipsen
Listed as NCT00149240, this PHASE2 trial focuses on Myofascial Pain Syndromes and remains completed. Sponsored by Ipsen, it has been updated 8 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Aug 2019 — Dec 2019 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Apr 2019 — Aug 2019 [monthly]
Completed PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jan 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .